What is the Evidence for the Use of Immunomodulatory Agents to Eradicate Inhibitory Antibodies in Patients with Severe Hemophilia A Who Have Previously Failed to Respond to Immune Tolerance Induction? | Zendy

Michael U. Callaghan | Zendy; Patrick F. Fogarty | Zendy

Open Access

What is the Evidence for the Use of Immunomodulatory Agents to Eradicate Inhibitory Antibodies in Patients with Severe Hemophilia A Who Have Previously Failed to Respond to Immune Tolerance Induction?

Author(s) -

Michael U. Callaghan,

Patrick F. Fogarty

Publication year - 2011

Publication title -

hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.321

H-Index - 91

eISSN - 1520-4391

pISSN - 1520-4383

DOI - 10.1182/asheducation-2011.1.405

Subject(s) - antibody , medicine , immunology , immune tolerance , immune system , titer , inhibitory postsynaptic potential , pharmacology

An 18-year-old man has severe hemophilia A that has been complicated by a high-titer inhibitory antibody (peak 170 BU/mL). He had previously failed a trial of immune tolerance induction (ITI) using daily high-dose (100 units/kg/d) factor VIII (FVIII) for 20 months and would like to know if immunomodulatory agents, with or without another course of ITI, might eradicate the inhibitor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research